Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PDS Biotechnology ( (PDSB) ) has shared an announcement.
On April 24, 2026, PDS Biotechnology updated its corporate presentation, highlighting the advancement of its Versamune-based oncology pipeline led by PDS0101 for HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma. The company reported a 77.4% disease control rate and a 39.3-month median overall survival for PDS0101 in first-line HPV16+ head and neck cancer, positioning the candidate against current standards such as Keytruda plus chemotherapy.
The updated deck underscores FDA alignment on using progression-free survival as an interim primary endpoint in the pivotal Phase 3 VERSATILE-003 trial, potentially enabling an accelerated route to approval. PDS Biotech also emphasized that HPV16+ tumors represent the largest and fastest-growing segment of head and neck cancers, lack targeted therapies and have worse survival, which, together with its expanding collaborations and multi-indication pipeline, could enhance its competitive standing in immuno-oncology and attract heightened stakeholder attention to future trial readouts.
The most recent analyst rating on (PDSB) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.
Spark’s Take on PDSB Stock
According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue losses, ongoing cash burn, and sharply higher leverage/low equity in 2025). Technicals are supportive due to a strong uptrend but are tempered by overbought momentum signals. Valuation remains challenged because the company is loss-making with no dividend support, while the earnings call adds some offset from positive clinical/regulatory progress despite near-term funding and execution uncertainties.
To see Spark’s full report on PDSB stock, click here.
More about PDS Biotechnology
PDS Biotechnology is a clinical-stage biopharmaceutical company focused on immuno-oncology, developing precision-designed cancer immunotherapies based on its Versamune platform. Its lead product candidate, PDS0101, targets HPV16-positive cancers, particularly head and neck squamous cell carcinoma, with additional pipeline programs including PDS01ADC across multiple difficult-to-treat tumor types.
The company concentrates on HPV16-driven malignancies, an area of growing incidence with limited targeted options and poor outcomes, aiming to collaborate with major cancer centers such as MD Anderson, Mayo Clinic and the U.S. National Cancer Institute. Its strategy is to leverage Versamune’s T cell–activating properties to improve survival in HPV16+ cancers and expand into liver-associated and prostate cancers via combination regimens and antibody-drug conjugates.
Average Trading Volume: 736,218
Technical Sentiment Signal: Sell
Current Market Cap: $51.8M
See more data about PDSB stock on TipRanks’ Stock Analysis page.